Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume 29, Issue 4, Pages 402-415
Publisher
Springer Nature
Online
2016-02-19
DOI
10.1038/modpathol.2016.40
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma
- (2014) Anais Laforest et al. EUROPEAN JOURNAL OF CANCER
- Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma
- (2014) Sun-Young Jun et al. MODERN PATHOLOGY
- Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
- (2014) Yu Imamura et al. Molecular Cancer
- Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study
- (2013) T Aparicio et al. BRITISH JOURNAL OF CANCER
- Small bowel adenocarcinomas—existing evidence and evolving paradigms
- (2013) Kanwal Raghav et al. Nature Reviews Clinical Oncology
- A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma
- (2012) Xiao Jun Xiang et al. ANTI-CANCER DRUGS
- KRASG>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma
- (2012) Tao Fu et al. INTERNATIONAL JOURNAL OF CANCER
- Genetics and epigenetics of small bowel adenocarcinoma: the interactions of CIN, MSI and CIMP
- (2011) Arne Warth et al. MODERN PATHOLOGY
- Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study
- (2010) A. Zaanan et al. ANNALS OF ONCOLOGY
- KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications
- (2010) Antoine Italiano et al. ANNALS OF SURGICAL ONCOLOGY
- Cetuximab in small bowel adenocarcinoma: a new friend?
- (2010) D Santini et al. BRITISH JOURNAL OF CANCER
- Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy
- (2010) Aziz Zaanan et al. CANCER
- Molecular characterisation and cetuximab-based treatment in a patient with refractory small bowel adenocarcinoma
- (2010) S. De Dosso et al. GUT
- Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases
- (2010) Hee-Kyung Chang et al. HUMAN PATHOLOGY
- KRAS Mutation and Microsatellite Instability: Two Genetic Markers of Early Tumor Development That Influence the Prognosis of Colorectal Cancer
- (2009) Garrett M. Nash et al. ANNALS OF SURGICAL ONCOLOGY
- Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine
- (2009) M J Overman et al. BRITISH JOURNAL OF CANCER
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
- (2008) Volker Heinemann et al. CANCER TREATMENT REVIEWS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started